This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Spectrum Pharmaceuticals (SPPI) Q3 Earnings: What's in Store?
by Zacks Equity Research
Spectrum Pharmaceuticals' (SPPI) Folotyn and Evomela drugs are expected to drive third-quarter sales. The company is progressing well with its pipeline candidates.
Is ACADIA (ACAD) Likely to Beat Earnings Estimates in Q3?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) antipsychotic drug, Nuplazid, is expected to record strong sales in the third quarter despite increased prices backed by higher demand.
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caladrius Biosciences, Orexigen Therapeutics, Sangamo Therapeutics and Syndax Pharmaceuticals
Why These 4 Biotech Stocks May Not Lose Momentum Soon
by Zacks Equity Research
The biotech industry has shown strength so far this year. The momentum is likely to continue for some time, it's a good idea to pick a few stocks that are unlikely to lose their momentum soon.
Why Earnings Season Could Be Great for Syndax Pharmaceuticals (SNDX)
by Zacks Equity Research
Syndax Pharmaceuticals (SNDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP ahead of earnings.
Can Jazz Pharma (JAZZ) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
Jazz Pharma's (JAZZ) lead drug, Xyrem, is likely to deliver a strong performance in Q2, thanks to label expansion efforts.
Inovio (INO) Q2 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Inovio Pharmaceuticals' (INO) most advanced pipeline candidate, VGX-3100 vaccine's consistent progress might drive the stock in Q2. However, lack of an approved product in portfolio is a dampener.
What's in Store for Puma (PBYI) this Earnings Season?
by Zacks Equity Research
Recent approval of Puma's (PBYI) lead candidate, neratinib, by the FDA might offer a huge boost to the company in Q2, though no sales from the drug will be recorded during the same.
What's in Store for Arena (ARNA) this Earnings Season?
by Zacks Equity Research
Although Belviq, the only approved product in Arena's (ARNA) portfolio, has an unimpressive performance so far, the company's efforts to improve the drug's performance might drive the stock in Q2.
Will ACADIA (ACAD) Pull Off a Surprise this Earnings Season?
by Zacks Equity Research
ACADIA Pharmaceuticals' (ACAD) Nuplazid is expected to maintain the growth trend, established since its launch, in the second quarter.
Repros (RPRX) Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Lack of revenues in Repros Therapeutics' (RPRX) product portfolio could be a concern. But the company's most advanced pipeline candidates -- enclomiphene and Proellex -- might better its results in Q2.
Can Ligand (LGND) Pull a Surprise This Earnings Season?
by Zacks Equity Research
Milestone payment on Baxdela's approval in the U.S. leveraging Ligand's (LGND) Captisol formulation technology and partnerships with leading healthcare companies, might drive the company in Q2.
GW Pharmaceuticals (GWPH) Q3 Earnings: What Lies in Store?
by Zacks Equity Research
Investors will likely be looking at GW Pharmaceuticals' (GWPH) progress with its anti-epileptic pipeline candidate, Epidiolex in its fiscal third-quarter results.
Can Mallinckrodt (MNK) Deliver a Beat this Earnings Season?
by Zacks Equity Research
Investor focus is likely to be on Mallinckrodt plc's (MNK) progress with its strategic acquisitions and pipeline updates.
What's in the Cards for Adverum (ADVM) this Earnings Season?
by Zacks Equity Research
Investors will be looking at Adverum's (ADVM) updates on progress of its various pipeline candidates.
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
by Zacks Equity Research
Merrimack Pharmaceuticals, Inc. (MACK) is expected to report first-quarter 2017 results around May 1. Last quarter, Merrimack missed bottom line expectations
Intrexon (XON): Will the Stock Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Intrexon Corporation (XON) is scheduled to report fourth-quarter 2016 results on Mar 1, after the market closes.
Agenus (AGEN): What's Ahead for the Stock in Q4 Earnings?
by Zacks Equity Research
Agenus Inc. (AGEN) is expected to report fourth-quarter 2016 results during this month.
Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Puma Biotechnology, Inc. (PBYI) is expected to report fourth-quarter 2016 results next month. The company has a mixed earnings history.
Arena Pharmaceuticals (ARNA) Q4 Earnings: What to Expect?
by Zacks Equity Research
Arena Pharmaceuticals, Inc. (ARNA) is expected to report fourth-quarter 2016 results next month.
Keryx (KERX) Q4 Earnings: What's in Store for the Stock?
by Zacks Equity Research
Keryx Biopharmaceuticals, Inc. (KERX) is expected to report fourth-quarter 2016 results on Mar 1.
ACADIA Pharma (ACAD) Q4 Earnings: What's in Store this Time?
by Zacks Equity Research
ACADIA Pharmaceuticals Inc. (ACAD) is expected to report fourth-quarter 2016 results on Feb 28.
Jazz Pharma (JAZZ) Q4 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Jazz Pharmaceuticals plc (JAZZ) is scheduled to report fourth-quarter 2016 results on Feb 28 after the market closes.